(Q37992593)

26 August 2017

Peroxisome proliferator-activated receptor (PPAR α/γ) agonists as a potential target to reduce cardiovascular risk in diabetes (English)

1 reference

26 August 2017

Stephen J Nicholls

1

1 reference

PubMed ID

22407927

26 August 2017

Kiyoko Uno

series ordinal

2

1 reference

PubMed ID

22407927

26 August 2017

language of work or name

English

0 references

publication date

9 March 2012

1 reference

Diabetes and Vascular Disease Research

26 August 2017

1 reference

26 August 2017

9

1 reference

26 August 2017

2

1 reference

26 August 2017

89-94

1 reference

Prevention of overweight/obesity as a strategy to optimize cardiovascular health

26 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Macrovascular effects and safety issues of therapies for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Prospective study of small LDLs as a risk factor for non-insulin dependent diabetes mellitus in elderly men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

The pathologic continuum of diabetic vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

The clinical relevance of LDL size and subclasses modulation in patients with type-2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

The mechanisms of action of PPARs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Medicinal Chemistry and Actions of Dual and Pan PPAR Modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Novel approach to treat insulin resistance, type 2 diabetes, and the metabolic syndrome: simultaneous activation of PPARalpha, PPARgamma, and PPARdelta

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Peroxisome proliferator-activated receptor-alpha and atherosclerosis: from basic mechanisms to clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Lipids, lipoproteins, and peroxisome proliferator activated receptor-delta

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

PPARalpha: an emerging therapeutic target in diabetic microvascular damage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Peroxisome proliferator-activated receptor-α activation promotes macrophage reverse cholesterol transport through a liver X receptor-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

The organization, promoter analysis, and expression of the human PPARgamma gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Investigational PPAR-gamma agonists for the treatment of Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

PPAR-gamma activation as an anti-inflammatory therapy for respiratory virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

PPARdelta/beta: the lobbyist switching macrophage allegiance in favor of metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Effect of fenofibrate on plasma lipoprotein composition and kinetics in patients with complete hepatic lipase deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Effects of combination lipid therapy in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical Studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

The effects of rosiglitazone on atherosclerotic progression in patients with Type 2 diabetes at high cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

A multicentre, randomized, double-blind placebo-controlled trial evaluating rosiglitazone for the prevention of atherosclerosis progression after coronary artery bypass graft surgery in patients with type 2 diabetes. Design and rationale of the VeIn

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with c

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Gene Expression Changes Induced by PPAR Gamma Agonists in Animal and Human Liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Effect of pioglitazone on various parameters of insulin resistance including lipoprotein subclass according to particle size by a gel-permeation high-performance liquid chromatography in newly diagnosed patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Thiazolidinediones, Peripheral Edema, and Type 2 Diabetes: Incidence, Pathophysiology, and Clinical Implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Combined thiazolidinedione-insulin therapy: should we be concerned about safety?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monother

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441477

21 January 2018

Identifiers

DOI

10.1177/1479164112441477

1 reference

26 August 2017

1 reference

PubMed ID

22407927